[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"resistant-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:resistant-hypertension":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,78,109,135,173,196,217,242,263,291,314,341,367,390,416],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100643375","phase-3-a-study-evaluating-aprocitentan-tabletssyh9108-for-the-treatment-of-resistant-hypertension-100643375",false,"NCT07635914","A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Aprocitentan Tablets in the Treatment of Resistant Hypertension","Inclusion Criteria:\n\n1. Male or female participants must be ≥18 years of age.\n2. Participants must have received stable doses of ≥3 antihypertensive agents from distinct pharmacological classes for at least 4 weeks prior to signing the ICF, with such therapy maintained until randomization.\n3. During the screening period and prior to randomization, SiSBP ≥140 mmHg with or without SiDBP ≥90 mmHg, and SiSBP \\\u003C180 mmHg and SiDBP \\\u003C110 mmHg.\n4. Participants are able to understand and cooperate in completing this trial, voluntarily participate in the trial, and sign the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n1. Presence of secondary hypertension.\n2. Have had transient ischemic attack, stroke, unstable angina pectoris, or acute myocardial infarction occurring within the period from 12 months prior to signing the ICF up to randomization.\n3. From screening to prior to randomization, have presence of uncontrolled severe disease or life-threatening disease, or failure to recover from major surgery, or prior thyroid surgery, or presence of malignant tumor, or meeting the criteria for severe hepatic insufficiency at screening.\n4. Have had unstable cardiac disease occurring within the period from 6 months prior to signing the ICF up to randomization.\n5. Have received dialysis at any time prior to signing the ICF or prior to randomization.\n6. Type 1 diabetes.\n7. Compliance with any background antihypertensive drug or placebo is \\\u003C80% or \\>120% during the run-in period.\n8. Use of endothelin receptor antagonists, antihypertensive drugs other than background medications, or other blood pressure-affecting drugs, or high-dose loop diuretics from 4 weeks prior to signing the ICF until randomization; or use of oligonucleotide antihypertensive agents within 1 year prior to signing the ICF.\n9. Hypersensitivity or suspected hypersensitivity to the excipients of the investigational product, endothelin receptor antagonists, or background antihypertensive drugs, or potential hypersensitivity to the investigational product.\n10. Participated in other clinical trials and received at least one dose of study treatment within 12 weeks prior to signing the ICF.\n11. Average night shifts are ≥ 2 times per week during the 4 weeks prior to signing the ICF, the screening period, the run-in period, or the anticipated study period.\n12. History of drug abuse or alcohol abuse within 5 years prior to signing the ICF.\n13. Any of the following test results during the screening period or prior to randomization:\n\n1\\) BMI≥37.5 kg\u002Fm2. 2) Hemoglobin \\\u003C 100 g\u002FL; 3) NT-proBNP ≥ 500 pg\u002FmL; 4) QTcF: \\> 450 ms in males, \\> 470 ms in females; 5) eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m²; 6) ALT or AST \\> 3 × ULN, or total bilirubin \\> 1.5 × ULN; 7) HbA1c \\> 8.0%; 8) TSH outside the normal range and FT3 and\u002For FT4 outside the normal range; 9) Positive HBsAg and positive HBV-DNA, or positive for any of anti-HCV antibody, anti-HIV antibody, anti-Treponema pallidum antibody.\n\n14\\. Female participants of childbearing potential who are pregnant, breastfeeding, or have a positive pregnancy test from signing the ICF until randomization; or female participants of childbearing potential and male participants who plan to conceive (including sperm or egg donation) and\u002For are unable to use effective contraceptive methods during the study period and within 30 days after the end of treatment.","ALL","18 Years",{"count":19,"type":20},382,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)",[26],"Resistant Hypertension",[28,29,30,31],"Resistant hypertension","rHTN","Aprocitentan","SYH9108","NOT_YET_RECRUITING","2026-06-03",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":20},"2026-05-31",{"date":40,"type":20},"2030-05-31",{"name":42,"class":43},"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100529089","early-phase-1-effect-of-nitrate-supplementation-on-blood-pressure-and-microvascular-function-of-resistant-hypertensive-patients-100529089","NCT06169241","Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients","Effect of Nitrate Supplementation on Blood Pressure and Systemic Microvascular Function of Resistant Hypertensive Patients","Inclusion Criteria:\n\n* Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days.\n\nExclusion Criteria:\n\n* neoplasms\n* heart failure\n* use of medications with nitrate in their formula\n* patients undergoing renal denervation","75 Years",{"count":53,"type":20},50,[55],"EARLY_PHASE1","Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.",[58,26,59,60],"Arterial Hypertension","Microvascular Function","Nitrate Supplementation",[62,63,64,65],"microcirculation","capillary density","microvascular reactivity","systemic resistant hypertension","RECRUITING","2026-04-07",{"date":69,"type":36},"2026-04-13",{"date":71,"type":36},"2023-11-01",{"date":73,"type":20},"2026-12",{"name":75,"class":76},"National Institute of Cardiology, Laranjeiras, Brazil","OTHER_GOV",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":77},"100583763","the-resplash-study-100583763","NCT06880562","The RESPLASH Study","Renal and Splanchnic Sympathetic Denervation as an Alternative Therapy for Resistant Hypertension and Type 2 Diabetes (RESPLASH Study)","Inclusion Criteria:\n\n* Patients aged 18-75.\n* History of Type 2 Diabetes Mellitus at least 5 years prior to enrollment.\n* HbA1c level ≥6.5%\n* Use of at least 1 oral antidiabetic agent and no changes in the last 30 days.\n* History of essential hypertension with systolic Blood pressure of 160 mmHg or more (≥150 mmHg in patient with Type 2 Diabetes Mellitus), despite compliance with three of more antihypertensive drugs.\n* Stable drug regimen of at least 3 antihypertensive medications with no changes for 2 weeks before enrollment.\n\nExclusion Criteria:\n\n* Estimated glomerular filtration rate of less than 30 mL\u002Fmin per 1.73m2.\n* Type 1 diabetes mellitus.\n* History of aortic pathologies such as aneurysm or dissection confirmed by immediate preprocedural angiography that would preclude the Endovascular Denervation (EDN) procedure.\n* Orthostatic hypotension.\n* Acute or severe systemic infection.\n* History of myocardial infarction, unstable angina, or cerebrovascular accident in the previous 3 months.\n* History of previous renal artery CDN.\n* Pregnancy or planned pregnancy during the study period.\n* Unable to provide informed consent.",{"count":86,"type":20},20,[88],"NA","To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.",[26],[92,93,94,95,96,97,98],"Renal Sympathetic Denervation","Splanchnic Sympathetic Denervation","Hypertension","Diabetes mellitus","Catheter-based radiofrequency ablation","Lowering blood pressure","Control of glycemic levels","2026-02-27",{"date":101,"type":36},"2026-03-03",{"date":103,"type":20},"2026-06",{"date":105,"type":20},"2027-06",{"name":107,"class":108},"Tulane University","OTHER",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":77},"100392294","phase-2-endothelin-1-receptor-blockade-in-resistant-hypertension-100392294","NCT04388124","Endothelin-1 Receptor Blockade in Resistant Hypertension","VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION","ENDOTHELIN-2","Inclusion Criteria:\n\n* age between 30 and 80 years old\n* Patients with resistant hypertension defined according to the criteria recognized by the French Society of Hypertension (SFHTA): arterial pressure greater than or equal to 140 and \u002F 90 mm Hg under triple antihypertensive therapy at optimal dose comprising at least one diuretic pendant at less than 4 weeks.\n* Patients with resistant hypertension confirmed by self-measurement (≥135 \u002F 85 mmHg on average) or by ambulatory blood pressure measurement (mean of 24h ≥130 \u002F 80 mmHg).\n* Hemoglobin level ≥ 12 g \u002F dL\n* For women of childbearing potential, reliable methods of contraception (as defined by the WHO-Pearl Index) should be used (hormonal contraception should not be the only contraceptive method used during bosentan treatment).\n* For postmenopausal women: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months and age greater than 45, before the inclusion visit)\n* Patient who read and understood the newsletter and signed the consent form\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Patients with hypertension\n* Patients with secondary arterial hypertension other than sleep apnea syndrome or chronic renal failure stage 2 or 3.\n* Patients with hypertension greater than or equal to 180 and \u002F or 110mmHg\n* Chronic renal failure stage 4 and 5 (defined by DFG CKD-EPI \\\u003C30 ml \u002F min \u002F 1,73m²)\n* Renal transplant patient XML File Identifier: CEyMau8sPo+QFyOLD1ZEY3ZGFow= Page 11\u002F22\n* Orthostatic hypotension (decreased SBP\\> 20mmHg and \u002F or DBP\\> 10mmHg occurring within 3 minutes of standing).\n* Contra-indication to NATISPRAY 0.30 mg \u002F dose, oral spray solution (including nitrate hypersensitivity) in accordance with the NATISPRAY\n\nSPC:\n\n* shock, severe hypotension,\n* in combination with sildenafil\n* obstructive cardiomyopathy,\n* inferior court inferior myocardial infarction with right ventricular extension, except in case of evidence of left ventricular failure,\n* intracranial hypertension,\n\n  • Contra-indication to BOSENTAN MYLAN 62.5 mg and 125 mg filmcoated tablets:\n* Hypersensitivity to the active substance or to any of the excipients listed in the SPC Moderate to severe hepatic insufficiency corresponding to class B or C of the Child-Pugh classification\n* Serum levels of liver aminotransferases, ASAT and \u002F or ALAT\\> 3 times the upper limit of normal at start of treatment (results less than 3 months old).\n* Association with ciclosporin A\n\n  * Known allergy to cellulose\n  * Patients treated with: tacrolimus or sirolimus, fluconazole or other CYP2C9 or CYP3A4 inhibitors, glibenclamide, rifampicin, antiretroviral drugs including lopinavir + ritonavir, warfarin, simvastatin, ketoconazole, epoprostenol, sildenafil and digoxin\n  * Pregnant, breastfeeding woman, or woman of childbearing potential not using reliable methods of contraception (hormonal contraception should not be the only contraceptive method used during bosentan treatment) or no proven reliable effective contraception;\n  * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice, under tutorship or curatorship\n  * Patient participating or having participated in the 4 weeks prior to inclusion in a clinical trial","80 Years",{"count":119,"type":20},24,[121],"PHASE2","The management of patients with resistant arterial hypertension, who are characterized by a very high cardiovascular risk, remains a major therapeutic issue. The use of endothelin-1 (ET-1) receptor antagonists, in addition to lowering blood pressure, may also improve endothelial function in these patients. The objective of this study is to assess the vascular impact of an ET-1 receptor antagonist on vascular function and systemic and central hemodynamics in patients with resistant arterial hypertension and ensure their good renal tolerance.",[26],[125],"endothelin-1","2026-02-12",{"date":128,"type":36},"2026-02-17",{"date":130,"type":36},"2021-10-20",{"date":132,"type":20},"2026-08",{"name":134,"class":108},"University Hospital, Rouen",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":155,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":77},"100622407","effect-of-electrical-stimulation-and-exercise-on-blood-flow-in-patients-with-resistant-high-blood-pressure-100622407","NCT07383220","Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure","Effect of Combined Transcutaneous Electrical Stimulation and Isometric Exercise on Peripheral Hemodynamic Parameters in Patients With Resistant Hypertension","Inclusion Criteria:\n\n* Age between 50 and 60 years. Both sexes were included Patients had been diagnosed with hypertension for at least 5 years.\n\nPatients had resistant hypertension according to (Whelton et al 2018), defined as:\n\n* Systolic blood pressure (SBP) ≥140 mmHg and\u002For diastolic blood pressure (DBP) ≥90 mmHg despite the use of three or more antihypertensive medications of different classes, including a diuretic,\n* or controlled blood pressure (\\\u003C140\u002F90 mmHg) while on four or more antihypertensive medications.\n\nBody Mass Index (BMI) 25: 34.9 kg\u002Fm²\n\nIncreased waist circumference, defined as:\n\n* Greater than 102 cm for males.\n* Greater than 88 cm for females.\n\nExclusion Criteria:\n\n* Secondary hypertension due to identifiable causes (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma).\n* History of major cardiovascular events in the last 6 months (e.g., myocardial infarction, stroke, or heart failure exacerbation).\n* Severe musculoskeletal or neurological disorders that impair the ability to perform isometric exercise safely (e.g., recent joint replacement, severe osteoarthritis, stroke with residual motor deficit).\n* Contraindications to the use of Transcutaneous Electrical Nerve Stimulation (TENS):\n\nImplanted electronic devices: pacemakers, cardioverter defibrillators. Uncontrolled arrhythmias. Sever skin condition: open wounds, rashes, burns, eczema. Peripheral neuropathy or sensory loss.\n\n-Known cognitive impairment or psychiatric conditions that would limit the ability to follow instructions or provide informed consent.","50 Years","60 Years",{"count":53,"type":20},[88],"The goal of this clinical trial is to learn if the combination between transcutaneous electrical nerve stimulation (TENS) and isometric exercise (IE) can improve blood pressure in men and women between 50 to 60 years old suffered from resistant hypertension which is a type of hypertension where blood pressure remains above your target goal despite the use of three or more different classes of antihypertensive medications at their maximum tolerated doses. The main question to answer is:\n\nIs there a significant effect on the combined use of TENS and IE on peripheral hemodynamic parameters in patients with resistant hypertension? Total sample will be 50 patients from both sexes\n\nI will compare between two groups:\n\nExperimental group (15 men, 10 women) will take: medication plus IE and TENS Control group (15 men, 10 women) will take: medication plus Conventional Physical Therapy Program",[26,148,149,150,151,152,153,154],"Hemodynamic Instability","Essential (Primary) Hypertension","Abdominal Obesity","Metabolic Syndrome","Hypertension (HTN)","Vascular Resistance","High Blood Pressure",[156,157,158,159,160,161,162,163],"Mean Arterial Pressure","Peripheral Hemodynamics","Physical Therapy","Long Term Hypertension","Resistant HTN","Systolic Blood Pressure (SBP)","Diastolic Blood Pressure (DBP)","Heart Rate Variability (HRV)","2026-01-28",{"date":166,"type":36},"2026-02-03",{"date":168,"type":20},"2026-01-15",{"date":170,"type":20},"2026-06-10",{"name":172,"class":108},"Mohamed Mohamed Ali Morgan",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":180,"maxAge":117,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100556573","early-feasibility-study-of-hyperquretm-rdn-system-laparoscopic-renal-denervation-therapy-in-patients-with-resistant-hypertension-100556573","NCT06526858","Early Feasibility Study of \"HyperQureTM RDN System\", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension","A Prospective, Multicenter, Single Arm, Open-label, Early Feasibility Study to Evaluate Initial Safety and Device Design Concept of \"HyperQureTM RDN System\", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension on Three(3) or More Antihypertensive Medications","Inclusion Criteria:\n\nSubjects are eligible to participate if all of the following criteria are met:\n\n1. Aged ≥22 and ≤80 years old at time of enrollment (consent).\n2. Diagnosed with resistant hypertension.\n3. Office BP ≥140\u002F90 mmHg at Screening Visit 1, and on at least 3 antihypertensive medications of different classes including a diuretic for at least 4 weeks prior to consent.\n4. Daytime ABP ≥135\u002F85 mmHg after a four (4)-week run-in period at Screening Visit 2.\n5. Agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.\n\nExclusion Criteria:\n\nSubjects are not eligible to participate if any of the following criteria are met:\n\n1. Has coverage diameter of renal artery less than 2 mm or greater than 11 mm.\n2. Has one or more of the following conditions:\n\n   1. Unstable angina with stent implantation (percutaneous coronary intervention) within 3 months of enrolment.\n   2. Myocardial infarction within 3 months of enrollment.\n   3. Acute heart failure (New York Heart Association (NYHA) III-IV) within 3 months of enrollment\n   4. Cerebrovascular accident or transient ischemic attack within 3 months of enrollment.\n   5. Atrial fibrillation patients undergoing treatment and not in sinus rhythm. Notes: Patients who have received medical treatment, catheter or surgical treatment for atrial fibrillation and are in sinus rhythm are not excluded\n3. Has one or more of the following confirmed anatomical findings in the kidney or renal artery that are not suitable for renal denervation (assessed by the renal CT angiography of Screening 2)\n\n   1. A single functioning kidney.\n   2. An atheroma, aneurysm or renal artery stent within 5 mm of the renal denervation site.\n   3. Presence of stenosis of 30% or more on all of the blood vessels available for renal denervation therapy.\n   4. When it is deemed impossible to perform denervation on both renal arteries according to the discretion of the investigator.\n4. Has one or more of the following medical history or a history of surgery\u002Fprocedure that is not suitable for renal denervation therapy\n\n   1. Renal denervation therapy.\n   2. Polycystic kidney disease (PKD).\n   3. Atrophic kidney.\n   4. Kidney transplant.\n   5. Dialysis due to end-stage renal disease.\n   6. Any surgery performed on both kidneys. (except endoscopy type of surgery, i.e. endoscopic kidney stone removal)\n   7. FMD (Fibromuscular dysplasia)\n5. Has comorbidities or surgical\u002Fprocedural history that are not suitable for retroperitoneal approach\n\n   1. Surgical history through retroperitoneal approach.\n   2. Fibrosis in the retroperitoneal region.\n   3. Inflammation in the retroperitoneal region.\n   4. Severe obesity (body mass index (BMI) \\> 40 kg\u002Fm2)\n   5. Risk of increased intracranial pressure\n6. Has a history of any intervention for underlying renal artery pathology including stenting or balloon angioplasty.\n7. Individual has an eGFR of \\\u003C45 mL\u002Fmin\u002F1.73m2, using the 4 variable Modification of Diet in Renal Disease (MDRD) calculation (in mL\u002Fmin) per 1.73 m2 = 175 x Serum Cr-1.154 x age-0.203 x 1.212 (if patient is black) x 0.742 (if female).\n8. Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma Hb1Ac ≥ 9.0%).\n9. Has had a reduction of SBP of ≥20 mm Hg or DBP of ≥10 mm Hg within 3 minutes of standing coupled with symptoms during the screening process (at Screening Visit 2).\n10. Requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea (e.g., CPAP, BiPAP).\n11. Has documented primary pulmonary hypertension.\n12. Has an untreated secondary cause of hypertension (either known or suspected) or is taking drugs that increase sympathetic tone and could contribute to hypertension.\n13. Has a scheduled or planned surgery that, in the opinion of the Investigator, may affect study endpoints.\n14. Works night shifts.\n15. Has severe cardiac valve stenosis for which, in the opinion of the Investigator, a significant reduction of blood pressure is contraindicated.\n16. Is pregnant, nursing or planning to become pregnant during the course of the study follow-up (Note: Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to angiography).\n17. Has a known unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable, in the opinion of the Investigator, to comply with study follow-up requirements.\n18. Has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.\n19. Patients who are at high risk if taken off their anticoagulant and antiplatelet agents for a few days.\n20. Allergy, intolerance or contraindications to contrast medium.\n21. Prescribed any standard antihypertensive cardiovascular medication for other chronic conditions (e.g. ischemic heart disease) for less than 90 days before Screening visit 1 and whose discontinuation might pose serious risk to health.\n22. Has frequent intermittent or chronic pain that results in the treatment with non-steroidal anti-inflammatory drugs (NSAIDs) for two (2) or more days per week over the month prior to Screening Visit 2.\n23. Concurrent enrollment in any other investigational drug or device study(Participation in non-interventional Registries is acceptable).","22 Years",{"count":182,"type":20},15,[88],"HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of \"HyperQureTM RDN System\", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications",[26],"2025-11-27",{"date":188,"type":36},"2025-12-04",{"date":190,"type":36},"2024-11-21",{"date":192,"type":20},"2029-03-20",{"name":194,"class":43},"DeepQure Inc.",5,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},"100532745","a-first-in-human-study-of-hyperquretm-laparoscopic-renal-denervation-therapy-in-patient-with-resistant-hypertension-100532745","NCT06216808","A First-in-human Study of HyperQureTM\", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension","A Prospective, Multicenter, Single Arm, Open Label, First-in-human Study to Evaluate the Safety and Initial Efficacy of HyperQureTM, Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension on 3 or More Antihypertensive Medications","Inclusion Criteria:\n\nSubjects are deemed eligible for this clinical trial only if they meet all of the following criteria:\n\n1. Male and female patients aged between 19 and 79 years old\n2. Resistant hypertensive patients on stable regimen of at least 3 antihypertensive medications\\* for at least 4weeks prior Screening1 and those who are willing to continue existing antihypertensive medications during run- in period and till 3 months after surgery from Screening 1\n\n   * Patients on at least 3 antihypertensive medications of different classes including diuretics\n3. Those who meet the following blood pressure requirements:\n\n   \\[Screening 1\\]\n   * Office systolic blood pressure (SBP) ≥ 140 mmHg\n   * Office diastolic blood pressure (SBP) ≥ 90 mmHg\n\n   \\[Screening 2\\]\n   * Office SBP ≥ 140 mmHg\n   * Office DBP ≥ 90 mmHg\n   * Daytime ASBP ≥ 135 mmHg\n4. Those who have the ability and willingness to provide voluntary and written consent to participate in this clinical trial\n\nExclusion Criteria:\n\nSubjects cannot be enrolled in the clinical trial if they meet any of the following criteria\n\n1. Those with the following confirmed anatomical findings in the kidney or renal artery that are unsuitable for renal denervation (assessed based on the results of the renal CT angiography of Screening 2)\n\n   * If there is an atheroma or renal artery stent within 5 mm of the renal denervation site\n   * Presence of stenosis of 30% or more on all of the blood vessels available for renal denervation therapy\n   * When it is deemed impossible to perform denervation on both renal arteries according to the discretion of the investigator\n2. Those with a medical history or a history of surgery\u002Fprocedure that is unsuitable for renal denervation therapy\n\n   * Renal denervation therapy\n   * Renal artery stenting within 3 months prior to surgery\n   * Polycystic kidney disease (PKD)\n   * Atrophic kidney\n   * Kidney transplant\n   * Dialysis due to end-stage renal disease\n   * Any surgery performed on the both kidney\n   * FMD(Fibromuscular dysplasia)\n3. Those with a confirmed comorbidity or a history of surgery\u002Fprocedure that is unsuitable for posterior retroperitoneal approach required for renal denervation therapy\n\n   * Surgical history using the retroperitoneal approach\n   * Fibrosis of the retroperitoneal region\n   * Inflammation of the retroperitoneal region\n   * Extreme obesity (body mass index (BMI) \\> 40 kg\u002Fm2)\n   * Risk of elevated intracranial pressure\n4. eGFR\\* \\\u003C 45 mL\u002Fmin\u002F1.73 m2\n\n   * eGFR calculation formula (MDRD equation) 175 × (sCr)-1.154 × (age)-0.203 × (0.742 if female)\n5. Those with type 1 diabetes or uncontrolled type 2 diabetes\\*\n\n   * Uncontrolled type 2 diabetes: HbA1c ≥ 8.0%\n   * HbA1c will be tested in Screening 2 if the confirmed HbA1c result is from the test conducted 3 months before Screening 2 or if additional tests are deemed necessary according to the investigator discretion due to a history of inadequately controlled blood glucose level.\n6. Those who receive SGLT2 inhibitors or GLP-1 agonists within 90 days before Screening 1, or those who are expected to require treatment during the clinical trial period(but if on continuous medication without changes more than 90days can be enrolled)\n7. Those with at least a 20-mmHg decrease in office SBP or at least a 10-mmHg decrease in office DBP accompanied by symptoms, measured within 3 minutes of standing up during Screening 2(but if orthostatic hypotension is clearly due to Benign Prostatic Hyperplasia, subject can be enrolled)\n8. Those who are likely to experience safety problems due to blood pressure drop according to the discretion of the investigator (e.g., heart valve stenosis, peripheral vascular disease, aortic aneurysm, and high-risk groups for bleeding (thrombocytopenia, hemophilia, severe anemia, etc.)\n9. Those who have difficulty in measuring blood pressure accurately according to the discretion of the investigator (e.g., if the circumference of the upper arm is larger than the cuff size of the blood pressure monitor, those with arrhythmia, etc.)\n10. Those who have secondary hypertension or are receiving sympathomimetic drugs that affect hypertension\n11. Those with a history of the following cardiovascular diseases or accompanying diseases\n\n    * Myocardial infarction occurring within 3 months prior to Screening 1\n    * Stable\u002FUnstable angina occurring within 3 months prior to Screening 1\n    * Heart failure(NYHA classification III\\~IV) within 3 months prior to Screening 1\n    * Transient ischemic attack within 3 months prior to Screening 1\n    * Cerebrovascular seizures (e.g., subarachnoid hemorrhage, cerebral embolism, etc.) within 3 months prior to Screening 1\n    * Atrial fibrillation (except for those who have confirmed sinus rhythm after undergoing medicinal treatment or surgery such as catheterization for the treatment of atrial fibrillation)\n12. Those with primary pulmonary hypertension\n13. Those with confirmed bleeding diathesis, coagulation disorder, or refusal to receive transfusions\n14. Those with a history of peptic ulcer disease or gastrointestinal bleeding within 6 months prior to Screening 1\n15. Those who are chronically on oxygen-assisted or mechanical ventilation (e.g., CPAP, BiPAP) (however, usage due to sleep apnea is exempted)\n16. Those who have taken non-steroidal anti-inflammatory drugs (NSAIDs) twice or more per week for pain control within 1 month prior to Screening 2\n17. Those with a history of contraindications to the use of contrast agents, anaphylactic reactions, or uncontrolled allergic reactions\n18. Those receiving antiretroviral drug therapy due to HIV infection (except when there is a documented history of hypertension prior to initiation of antiretroviral drug therapy)\n19. Those with the following confirmed drug administration history in relation to narcotic drugs:\n\n    * A history of abuse of narcotic drugs\n    * Those who use methadone\n    * Those who have used narcotic drugs twice or more within 1 month prior to Screening 1\n20. Those with drug or alcohol dependence that has not been cured at the time of Screening 1, and who lack the ability or are unable to understand and follow the instructions required in this clinical trial\n21. Those who are scheduled to undergo a surgery\u002Fprocedure that is expected to affect the efficacy and safety of this clinical trial according to the discretion of the investigator\n22. Night shift workers\n23. Those who have received other investigational products or investigational medical devices within 4 weeks prior to Screening 1 (however, such patients may be enrolled if such products of devises do not affect the efficacy and safety assessment of this clinical trial according to the discretion of the investigator)\n24. Women who are pregnant, lactating, or plan to become pregnant during the period of the clinical trial\n25. Other subjects who are deemed ineligible to participate in this clinical trial according to the investigator's discretion","19 Years","79 Years",{"count":206,"type":20},10,[88],"HQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3 or more antihypertensive medications",[26],{"date":188,"type":36},{"date":212,"type":36},"2023-12-04",{"date":214,"type":20},"2026-12-04",{"name":194,"class":43},7,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":77},"100610852","phase-3-perirenal-adipose-tissue-modification-therapy-for-resistant-hypertension-100610852","NCT07232966","Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension","The Efficacy and Safety of Perirenal Adipose Tissue Modification Therapy by Focused Power Ultrasound for Resistant Hypertension","PATH-RHT","Inclusion Criteria:\n\n1. Male or female participants aged 18-75 years old;\n2. 24h ambulatory systolic BP ≥130mmHg and \\\u003C150mmHg, and 24h ambulatory diastolic BP \\\u003C100mmHg after at least 4 weeks of combined treatment with 3 antihypertensive drugs (including a diuretic);\n3. The ultrasound measured inferior perirenal adipose tissue ≥8 cm3 (with the superior-inferior diameter, left-right diameter, and anterior-posterior diameter all needing to be ≥20 mm);\n4. Be willing to participate in the trial, and be able to visit doctors by himself or herself;\n5. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Secondary hypertension;\n2. Occurrence of myocardial infarction, malignant arrhythmia, severe renal failure, or stroke within 6 months;\n3. Ambulatory BP monitoring was invalid (\\\u003C70% valid readings, or \\\u003C20 daytime readings or \\\u003C7 nighttime readings);\n4. Alanine transaminase (ALT), aspartate transaminase (AST), or total bilirubin (TBL) above twice the normal range; eGFR (CKD-EPI) \\\u003C45mL\u002Fmin\u002F1.73m2;\n5. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (glycated hemoglobin ≥8.5%);\n6. Single functionally normal kidney or presence of renal malignant tumor;\n7. Bilateral skin diseases at renal region that are not suitable for the therapy;\n8. Women in pregnancy, lactating, or planning for pregnancy;\n9. Other concomitant diseases that are considered not suitable for participation in the trial;\n10. Patients have contraindications to angiotensin receptor-neprilysin inhibitor (ARNIs), thiazide-like diuretic drugs, or calcium channel blocker (CCBs);\n11. Non-compliant patients.",{"count":226,"type":20},220,[23],"The goal of this clinical trial is to investigate if focused power ultrasound (FPU) targeted perirenal adipose tissue modification therapy would be effective and safe in treating resistant hypertension. The primary outcome of the study is the difference in the reduction of 24h mean systolic blood pressure between treatment and sham procedure groups 6 months after treatment. The secondary outcomes include the reduction of clinic blood pressure 1, 3, and 6 months after treatment, the reduction of 24h mean blood pressure 1, 3, and 6 months after treatment, and the drug burden of antihypertensive treatment. The safety evaluation includes the incidence of all-cause death, cardiovascular events (stroke and myocardial infarction), renal failure, and other adverse events.",[26],[231,232],"perirenal adipose tissue","focused ultrasound","2025-11-14",{"date":235,"type":36},"2025-11-18",{"date":237,"type":20},"2025-11-20",{"date":239,"type":20},"2029-06-30",{"name":241,"class":108},"Yan Li",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":77},"100599188","symplicity-china-study-100599188","NCT07081243","Symplicity China Study","A Prospective, Single-group, Non-interventional, Non-blinded, Observational Study to Evaluate the Long-term Safety, Efficacy, and Durability of Symplicity Spyral Renal Denervation System in China","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Patients diagnosed with resistant hypertension or antihypertensive drug intolerance and treated with Symplicity Spyral Renal Denervation System. Resistant hypertension, defined as having an office systolic blood pressure (SBP) ≥140 mmHg despite appropriate lifestyle measures and being treated with three or more antihypertensive medications (including a diuretic) for more than 3 months; or drug intolerance, defined as patients who cannot tolerate medication due to contraindications or adverse effects.\n3. The patient voluntarily undergoes renal denervation; the patient has been informed of the observational nature of the study; the patient voluntarily provides written informed consent (\"Patient Informed Consent Form\") and willingly participates in the study.\n\nExclusion Criteria:\n\n1. At least one main renal artery with a diameter less than 3 mm or greater than 8 mm.\n2. Presence of fibromuscular dysplasia.\n3. Renal artery stent placement within 3 months prior to the procedure.\n4. Presence of Renal artery aneurysms.\n5. Presence of more than 50% stenosis in any treatable vessel.\n6. Pregnant.\n7. Present of renal or adrenal tumors.\n8. Iliac\u002Ffemoral artery stenosis prevents catheter insertion.",{"count":250,"type":20},500,"OBSERVATIONAL","The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of follow up.",[26],"2025-11-13",{"date":256,"type":36},"2025-11-17",{"date":258,"type":36},"2025-11-11",{"date":260,"type":20},"2031-12-30",{"name":262,"class":43},"Medtronic Vascular",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":273,"conditions":274,"keywords":277,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":77},"100576085","smart-study-in-real-world-100576085","NCT06780696","SMART Study in Real World","Sympathetic Mapping and Ablation of Renal Nerves to Treat Uncontrolled Hypertension in Real World","SMART-RW","1. \\*\\*Inclusion Criteria (for A. Prospective Cohort)\\*\\*\n\n   * Patients are ≥18 years old;\n   * Patients with drug-resistant hypertension patients who are intolerant to drug therapy and, in either case, need to reduce medications;\n   * Patients consent to receive msRDN treatment using the commercially available msRDN system by SyMap Medical (Suzhou), Ltd and to fulfill follow-up requirements.\n2. \\*\\*Exclusion Criteria (for A. Prospective Cohort)\\*\\*\n\n   * Subjects are withdrawn from the study due to various reasons;\n   * Investigators, ethics committees or regulatory agencies may halt or terminate the study due to medical perspectives or ethical considerations.\n3. \\*\\*Inclusion Criteria (for B. Retrospective Cohort)\\*\\*\n\n   * Patients are ≥18 years old;\n   * Patients with drug-resistant hypertension patients who are intolerant to drug therapy and, in either case, need to reduce medications;\n   * Patients who have been received msRDN procedure using commercially available msRDN system by SyMap Medical (Suzhou), Ltd;\n4. \\*\\*Exclusion Criteria (for B. Retrospective Cohort) \\*\\*\n\n   * Subjects are withdrawn from the study due to various reasons;\n   * Investigators, ethics committees or regulatory agencies may halt or terminate the study due to medical perspectives or ethical considerations.",{"count":272,"type":20},1000,"This study is a multicenter, single-arm, open-label and post-market study in a real world patient population with uncontrolled hypertension to document the long-term safety and efficacy of a renal mapping\u002Fselective renal denervation (msRDN) system (SyMap Medical (Suzhou), Ltd, Suzhou, China) and conducted in accordance with the requirements by National Medical Production Administration (NMPA) of China. The msRDN system consists of a disposable renal artery radiofrequency ablation catheter (Registration No: National Medical Device Approval 20243011383), a console with both electronic stimulation and radiofrequency ablation function (Registration No: National Medical Device Approval 20243011384). The study includes prospective cohort and retrospective cohort.\n\nApproximately1,000 patients with uncontrolled hypertension who undergo msRDN procedure will be recruited from over 30 centers in China. Subjects enrolled in the study will be followed for at least three years after msRDN procedure. This study includes patients with drug-resistant hypertension or patients who are intolerant to drug therapy and, in either case, need to reduce antihypertensive medications per the inclusion criteria defined in the protocol.",[94,275,26,276],"Uncontrolled Hypertension","Reduce Antihypertensive Drug Burden",[278,279,280,281],"uncontrolled hypertension","hypertension","reduce antihypertensive medications","resistant hypertension","2025-02-13",{"date":284,"type":36},"2025-02-17",{"date":286,"type":20},"2025-02",{"date":288,"type":20},"2029-04",{"name":290,"class":43},"SyMap Medical (Suzhou), Ltd.",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":300,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":195},"100579049","self-management-of-blood-pressure-in-resistant-hypertension-100579049","NCT06819241","Self-Management of Blood Pressure in Resistant Hypertension","Effectiveness of Self-Management of Blood Pressure on the Management of Resistant Hypertension","Inclusion Criteria:\n\n1. ≥18 years of age\n2. receiving ≥3 antihypertensive medications of different classes, including a diuretic, and baseline BP \\>130\u002F80 mmHg; or receiving ≥ 4 medications regardless of BP\n\nExclusion Criteria:\n\n1. unable to conduct self-monitor BP because of cognitive dysfunction\n2. poor adherence to medication\n3. poor digital capabilities\n4. pregnant\n5. terminal disease\n6. an acute cardiovascular event in the previous 3 months",{"count":299,"type":20},600,[88],"The trial is a 12-month randomized, parallel-group study comparing three arms: (1) HBP self-management with AI chatbot support, (2) HBP self-management without AI chatbot support, and (3) usual care. The primary objective is to evaluate differences in blood pressure changes and medication compliance between groups at 6 and 12 months.",[26],[281,304],"self-management of blood pressure","2025-02-10",{"date":307,"type":36},"2025-02-11",{"date":309,"type":20},"2025-02-16",{"date":311,"type":20},"2027-10-31",{"name":313,"class":108},"Taichung Veterans General Hospital",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":321,"sex":16,"minAge":17,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":77},"100550688","resistant-hypertension-an-open-complicated-cum-plicare-or-complex-cum-plexus-syndrome-100550688","NCT06450327","Resistant Hypertension An Open, Complicated (\"Cum Plicare\") or Complex (\"Cum Plexus\") Syndrome?","Resistant Hypertension An Open, Complicated (\"Cum Plicare\") or Complex (\"Cum Plexus\")","Inclusion Criteria:\n\n* men and women over 35 years of age diagnosed with resistant arterial hypertension (RH), in accordance with the latest international and national guidelines;\n* be able to understand, verbalize and answer questions;\n* agree to participate in the study and sign the Informed Consent Form;\n* after clearly understanding it;\n* be under regular follow-up at the UNICAMP Cardiovascular Pharmacology outpatient clinic for at least six months;\n* have proven adherence to non-pharmacological and pharmacological treatment;\n* women in the reproductive phase must be using a proven effective contraceptive method.\n\nExclusion Criteria:\n\n* clinical history or clinical symptoms of heart failure;\n* patients with dilated cardiomyopathies, valvular heart disease, pericardial disorders;\n* patients with cerebrovascular disease or peripheral arterial disease, nephropathies, liver diseases, smoking, autoimmune diseases and use of illicit substances;\n* any abnormal condition that may interfere with the results of the study or the health of the volunteer, as judged by the researcher;\n* women who are pregnant or intend to become pregnant;\n* current participation in another investigative study;\n* major depression or other relevant psychiatric disorders.",true,"85 Years",{"count":324,"type":20},80,"Resistant arterial hypertension (RAH) is a complex and multifactorial syndrome, with hyperactivity of the sympathetic nervous system (SNS) and reduction of vagal activity being considered some of the main causes of refractoriness to treatment. Seen from the outside, it resembles a complicated (see lat. \"Cum plicate\") or complex disease (see lat. \"Cum plexus\"), Chaotic with the participation of several open systems. For example, in recent years some relationships have been demonstrated between the autonomic nervous systems, synaptic mediators, hormones, inflammatory and immune responses. However, these findings have not been investigated together and systematically. In the present project, we intend to establish and compare, in an integrated way, the clinical alterations present in RAH (resistant and refractory), hemodynamic variables, autonomous activity (sympathetic and baroreflex) and interactions with the neuroimmune-endocrine systems. To this end, we will test the hypothesis that resistant patients have greater damage to the autonomic nervous system (ANS) associated with exacerbated systemic and hormonal inflammatory profile, including SNA mediators (noradrenaline and acetylcholinesterase). This is also intended to determine the behavior (deterministic or chaotic) of the systems evaluated (mentioned above) in volunteers with RAH. Sample and methods: The sample space (calculated) will consist of 72 individuals, being: - 18 refractory hypertensive (HRT); II- 18 resistant hypertensive patients (HRfT); III- 18 controlled hypertensive (1-2 drugs) (CAH); and IV- 18 healthy normotensive individuals. This is a prospective, double-blind study (patient and professional-technician), paired (1 X 4), in which the 72 volunteers will be evaluated by the methods set out below. We will also have the chance to observe whether resistant and refractory hypertension share the same pathophysiological bases and clinical manifestations (\"deterministic-isolated or cardiovascular chaos\") by analyzing the patterns of cardiovascular variability (MAPA and Holter) (SpaceLabs, USA; DynaMap, Brazil), inflammatory and hormonal mediators (ELISA) in the resistant hypertension - RHT and refratary hypertension - HfRT groups. Central pressure (CP) and arterial stiffness (pulse wave velocity, VOP) (Sphymocor, ATCor, USA) will also be assessed. Healthy normotensive (NT) and controlled hypertension (CAH) will be evaluated in an identical way to control the other groups. Perspectives: The findings will improve the clinical knowledge based on pathophysiology about Resistant Hypertension and, mainly, the bases of pharmacological treatment and with implantable devices (stimulation of baroreceptors and sympathetic denervation) used in this condition.",[94,26],[328,281,329,330,331],"autonomic nervous system","arterial hypertension","refractory hypertension","baroreceptors","2024-08-28",{"date":334,"type":36},"2024-08-29",{"date":336,"type":36},"2024-08-27",{"date":338,"type":20},"2026-12-30",{"name":340,"class":108},"University of Campinas, Brazil",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":348,"maxAge":51,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":77},"100555723","evaluation-of-two-isometric-exercises-in-the-reduction-of-the-blood-pressure-in-people-with-resistant-hypertension-100555723","NCT06515795","Evaluation of Two Isometric Exercises in the Reduction of the Blood Pressure in People With Resistant Hypertension","Evaluation of the Safety and Efficacy of Two Isometric Exercises in the Reduction of the Blood Pressure in People With Resistant Hypertension","Inclusion Criteria:\n\n* Adults aged 40 to 75 years old, previously diagnosed with resistant hypertension, and on stable medication for at least 6 months.\n\nExclusion Criteria:\n\n* People with secondary hypertension, heart failure, peripheral artery disease, atrial fibrillation, chronic obstructive pulmonary disease or renal failure; people with a cerebro-cardiovascular event in the previous 3 months; people with changes in pharmacological therapy in the previous 6 months; trained people (with regular participation (≥ 2x\u002Fweek) in exercise training programs in the previous 3 months); people who have any contraindication to exercise; people with neurological and\u002F or orthopaedic conditions that will interfere with their participation in exercise, such as Parkinson's disease or knee osteoarthritis. Participants with low score (\\\u003C6) on the MMAS-8 will also be excluded.","40 Years",{"count":182,"type":20},[88],"Hypertension remains the main preventable cause of cardiovascular disease (CVD) and all-cause mortality, both in Europe and globally. Resistant hypertension, a severe phenotype of hypertension, is defined as a blood pressure (BP) that remains above the management goal despite using three different antihypertensive agents of different classes at the maximum or maximum tolerated dose, or controlled BP on four or more antihypertensive medications. Hypertension remains a poorly controlled risk factor on a global scale and the prevalence of resistant hypertension is also growing - it is now estimated to be around 10-20%.\n\nAt the moment, there is robust evidence establishing the antihypertensive effects of exercise. The acute reduction of BP after a single bout of exercise is known as post-exercise hypotension.\n\nIn recent years, the number of investigations into the benefits of isometric exercise in the treatment of hypertension has increased, due to its ease of access and potential for use. In a recently published meta-analysis, the authors pointed to isometric exercise as the most effective type of exercise in reducing systolic and diastolic BP.\n\nGiven the scarceness of data regarding the safety and efficacy of isometric exercise in individuals with resistant hypertension and since the acute response to exercise may help to identify people who respond to exercise as antihypertensive therapy, the objective of this study is to analyse the acute effect on BP levels of two different isometric exercises - isometric handgrip (IHG) and isometric wall squat (IWS), regarding safety and efficacy, in people with resistant hypertension.\n\nThe aim is to analyse if isometric exercises are safe in this population, through the assessment of BP during the execution of the exercises. Besides that, the comparison of IHG and IWS with the control session and between one and another, will help to understand which form of isometric exercise is most effective and has the longest lasting impact on reducing BP.\n\nEach participant must complete an acclimatization session, in which the procedures will be explained, data will be collected and the intensity of IHG and IWS will be assessed. Subsequently, each participant must complete three randomly assigned experimental sessions: a non-exercise control session and two exercise sessions, in which they will follow the protocols currently used in the literature (IHG at 30% of Maximum Voluntary Contraction and IWS at 95% of peak Heart Rate).",[26],[281,354,355,356,357],"isometric exercise","handgrip","wall squat","blood pressure","2024-07-17",{"date":360,"type":36},"2024-07-23",{"date":362,"type":36},"2024-07-11",{"date":364,"type":20},"2024-09",{"name":366,"class":108},"Universidade do Porto",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":16,"minAge":374,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":21,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100537767","effectiveness-and-safety-of-bisaae-for-resistant-hypertension-100537767","NCT06282107","Effectiveness and Safety of BiSAAE for Resistant Hypertension.","Effectiveness and Safety of Bilateral Superselective Adrenal Arterial Embolization (BiSAAE) for Resistant Hypertension","Inclusion Criteria:\n\n* Male or female, aged between 30-65 years old.\n* Patients with resist hypertension (office systolic blood pressure ≥140 mmHg, and\u002For office diastolic blood pressure ≥90 mmHg, and\u002For 24-h average systolic blood pressure ≥130 mmHg) with rational lifestyle change and triple antihypertensive drugs (irbesartanhydrochlorothiazide 162.5 mg\u002Fd, amlodipine 5 mg\u002Fd) for at least 4 weeks.\n* Informed consent signed and agreed to participate in this trial.\n\nExclusion Criteria:\n\n* Secondary hypertension\n* Adrenergic insufficiency.\n* adrenocortical insufficiency\n* Renal failure eGFR\\\u003C60 mL\u002Fmin\u002F1.73 m2\n* Heart failure with NYHA grade Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.\n* Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.\n* Liver dysfunction or the following history of liver disease: AST or ALT 3 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.\n* Fertile woman without contraceptives.\n* Coagulation dysfunction.\n* Pregnant women or lactating women.\n* Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.\n* Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.\n* Allergy or any contraindications for the study drugs, contrast agents and alcohol.\n\nHistory of depression, schizophrenia or vascular dementia.\n\n-Refused to sign informed consent","30 Years","65 Years",{"count":377,"type":20},72,[88],"Hypertension is a common problem, affecting \\>1.1 billion people worldwide. Unfortunately, fewer than one in five treated patients with hypertension have their blood pressure (BP) under control. The increasing number of people with uncontrolled BP despite the use of three or more antihypertensive agents at optimal or maximally tolerated doses, with one of those agents preferably being a diuretic has been described as the resistant hypertension (RH). Achieving BP control is essential because patients with hypertension who have uncontrolled BP have significantly higher rates of all-cause, cardiovascular, heart disease and cerebrovascular disease mortality compared to normotensive individuals, whereas mortality risk in patients with well-controlled BP does not differ from that in normotensive individuals. There are a number of potential factors that contribute to the suboptimal control of hypertension, including medication non-adherence and prescribing inertia. This highlights the limitations of purely pharmacological approaches for the effective management of hypertension. In fact, the activation of the renin-angiotensin-aldosterone system (RAAS) and sympatho-adrenomedullary system play a pathogenic role in triggering and sustaining RH. Superselective adrenal arterial embolization (SAAE) is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines. Over the last decade, unilateral SAAE has emerged as a potential treatment option for patients with primary aldosteronism. Whether this approach can be extrapolated to patients with RH is unclear. We thus set out to perform a randomized trial to compare the safety and efficacy of bilateral SAAE with antihypertensive medications in treating RH.",[26],"2024-02-27",{"date":383,"type":36},"2024-02-28",{"date":385,"type":20},"2025-01-01",{"date":387,"type":20},"2026-12-31",{"name":389,"class":108},"First Affiliated Hospital of Chengdu Medical College",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":399,"conditions":400,"keywords":404,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":77},"100533658","comparison-of-catecholamine-concentrations-in-venous-blood-during-selective-adrenal-artery-embolization-100533658","NCT06228677","Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization","Comparison of Catecholamine Concentrations in Adrenal Venous Blood and Peripheral Venous Blood During Percutaneous Selective Adrenal Artery Embolization in Hypertensive Patients With Primary Aldosteronism: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years with no gender restrictions.\n2. Adherence to the \"Primary Aldosteronism\" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.\n3. Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140\u002F90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure \\>130\u002F80 mmHg or daytime readings \\>135\u002F85 mmHg.\n4. Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.\n5. Hypertension history surpassing a duration of 6 months.\n6. Prior to screening, patients or their lawful guardians must provide a signed informed consent, sanctioned by the ethics committee.\n\nExclusion Criteria:\n\n1. Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.\n2. Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.\n3. Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.\n4. Pronounced allergic reaction to contrast agents.\n5. Any other serious systemic diseases with a life expectancy of less than 12 months.\n6. Participants concurrently enrolled or expressing interest to participate in other clinical trials, the outcomes of which could potentially influence the results of the current study.\n7. The researcher's discretion deems the subject inappropriate for inclusion in the study for any given reason.",{"count":398,"type":20},196,"To explore the relationship between perioperative blood pressure and catecholamine concentrations in adrenal venous blood and peripheral venous blood in hypertensive patients with primary aldosteronism (PA) who underwent percutaneous selective adrenal artery embolization (SAAE). In order to elucidate the related phenomena and possible mechanisms of blood pressure fluctuations caused by SAAE treatment in hypertensive patients with PA.",[26,401,402,403],"Secondary Hypertension","Secondary Hypertension to Endocrine Disorders","Primary Aldosteronism",[403,405,406,407,408],"Selective Adrenal Artery Embolization","catecholamine concentration","Adrenal Venous Blood","Blood Pressure Variability","2024-01-19",{"date":411,"type":36},"2024-01-29",{"date":413,"type":36},"2023-09-18",{"date":387,"type":20},{"name":389,"class":108},{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":423,"targetDuration":4,"studyType":21,"phases":425,"briefSummary":426,"conditions":427,"keywords":430,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":439,"locationsCount":4},"100515686","impact-of-renal-denervation-in-patients-with-coronary-microvascular-dysfunction-study-design-and-rationale-100515686","NCT05994729","Impact of Renal Denervation in Patients With Coronary Microvascular Dysfunction: Study Design and Rationale","IMPRESSION","Rul-in Phase Inclusion Criteria:\n\n* Non obstructive stable coronary artery disease (CAD) on invasive coronary angiography (defined as the absence of either \\>50% angiographic stenosis or any flow limiting lesion on functional evaluation)\n* Suspected diagnosis of difficult to control\u002F resistant hypertension for which renal denervation by radiofrequency ablation with Spyral Symplicity 3 could be considered.\n\nRule-in Phase Exclusion Criteria:\n\n* Initiation of either nitrates, beta-blocker or calcium channel blocker less than 30 days before the end of the rule-in phase\n* Physiological assessment performed during first medical contact documenting preserved coronary microvascular function\n* Physiological assessment performed at the \"first contact\" hospitalization followed by modification of medical therapy during the rule-in phase, before RDN\n* Acceptable blood pressure control after medical treatment optimization\n* Identification of secondary causes of hypertension\n* Renal artery anatomy not suitable for RDN\n* Ejection fraction below 30%\n* Life expectancy below 1 year\n* Indication to cardiac surgery\n* Adenosine allergy\n* Pregnancy\n* Large necrotic area documented by either MRI, SPECT or combination of ECG signs + Echocardiographic images.\n* Hemodynamic instability\n* Refuse to sign informed consent\n* Age below 18 or above 80\n\nStudy Phase Inclusion Criteria:\n\n* Having coronary microvascular dysfunction documented by invasive functional assessment (IMR\\>25 and or CFR \\\u003C 2)\n* Fulfilling all the rule-in phase inclusion criteria without any rule-in phase exclusion criteria\n\nStudy Phase Exclusion Criteria:\n\n* Refuse to sign informed consent\n* Evidence of newly detected obstructive CAD on invasive coronary angiography performed 6 months after RDN",{"count":424,"type":20},87,[88],"Long-standing hypertension may cause an impairment in microvascular coronary circulation which is involved in many different cardiac conditions. Renal denervation (RDN) has been successfully proven as a valuable and powerful therapeutic choice to consider for patients with resistant hypertension; moreover this procedure looks promising in other cardiac disease such as heart failure and atrial fibrillation, given its ability to downregulate sympathetic nervous system The aim of this study is to explore the effect of renal denervation and blood pressure control on coronary microvascular dysfunction.\n\nThis is a multicenter, prospective, non randomized, open-label, interventional study. Consecutive patients with resistant hypertension, non obstructive coronary artery disease and documented microvascular dysfunction will be enrolled. Patients will undergo renal denervation by Spyral Symplicity 3 and re-assessment of coronary microvascular function 12 months after the procedure. Primary endpoint will be the difference in average index of microcirculatory resistance value.",[428,26,429],"Coronary Microvascular Dysfunction","Hypertensive Heart Disease",[431,432],"MVD","HHD","2023-10-22",{"date":435,"type":36},"2023-10-24",{"date":437,"type":20},"2024-01-01",{"date":387,"type":20},{"name":440,"class":108},"Aurelia Hospital"]